Diagnostics beat implants in the race to market
Roche had the most innovative approvals over the last five years – but took second place in terms of speed.
The next generation of diabetes technology
New devices are coming, but the real advances will involve combinations.
Abbott finally enters the leadless pacemaker fray
Remember Nanostim? It’s back – in a modified form, sold by a different company, and under another name.
Embecta seeks high growth with low tech
The diabetes-focused Becton Dickinson spinoff intends to spend – but can it compete in insulin pumps?
